Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tapentadol controlled-release - Grunenthal/Janssen Research & Development/Ortho-McNeil

X
Drug Profile

Tapentadol controlled-release - Grunenthal/Janssen Research & Development/Ortho-McNeil

Alternative Names: BN200 ER; BN200 PR; CG 5503 ER; CG 5503 PR; JNS024ER; Nucynta ER; Palexia Depot; Palexia Retard; Palexia RP; Palexia SR; Palexia XR; R331333 PR; Tapenta; Tapentadol CR tamper-resistant formulation; Tapentadol CR TRF; Tapentadol ER PR2; Tapentadol ER prolonged-release 2; Tapentadol ER tamper-resistant formulation; Tapentadol ER TRF; Tapentadol extended release; Tapentadol PR; Tapentadol prolonged release; Tapentadol prolonged release granules; Yantil Retard

Latest Information Update: 17 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Grunenthal
  • Developer Collegium Pharmaceutical; Grunenthal; Janssen Pharmaceutical KK; Janssen Research & Development
  • Class Amines; Opioid analgesics; Phenols; Small molecules
  • Mechanism of Action Adrenergic uptake inhibitors; Alpha 2 adrenergic receptor antagonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cancer pain; Diabetic neuropathies; Pain
  • Discontinued Neuropathic pain

Most Recent Events

  • 31 Dec 2023 Preregistration for Pain (In children) in USA (PO) before December 2023
  • 09 Mar 2022 No development reported - Phase-II/III for Pain (In adolescents, In children) in Chile (PO)
  • 31 Dec 2021 Collegium Pharmaceutical files prior approval supplement for an alternate tapentadol CR manufacturing site
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top